Abstract
It is now widely accepted that adoptive transferred LAK cells plus interleukin-2 (IL-2) or induction of cytotoxic mechanisms by IL-2 alone may play an important role in cancer therapy [1–11]. Most of the available data comes from experimental and clinical studies of solid tumors, while only little is known about the effect of LAK cells against human leukemia [12–14]. Leukemia patients have been reported to show a deficiency in natural killer (NK) cell functions which may contribute to leukemogenesis. The possibility of correcting this deficiency by IL-2 may be of great value in the treatment of human leukemia [15, 16]. Our study aimed at investigating the ability of LAK cells to lyse fresh human leukemia cells in vitro and improving the efficacy of cytotoxic mechanisms by combined application of IL-2 and other lymphokines or cytokines.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson CG, Reichert CM (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485–1492
Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA (1986) Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma:phase I trial. Cancer Res 46:2101–2104
Lotze MT, Matory YL, Rayner AA, Ettinghausen SE, Vetto JT, Seipp CA, Rosenberg SA (1986) Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 58:2764–2772
Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A Progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889–897
West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK (1987) Constant-infusion of recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316:898–905
Ingram M, Shelden CH, Jacques S, Skillen RG, Bradley WG, Techy GB, Freshwater DB, Abts RM, Rand RW (1987) Preliminary clinical trial of immunotherapy for malignant glioma. J Biol Response Mod 6:489–498
Rosenberg SA (1988) Cancer therapy with interleukin-2:immunologic manipulations can mediate the regression of cancer in humans. J Clin Oncol 6:403–405
Mitchell MS, Kempf RA, Harel W, Shau H, Boswell WD, Lind S, Bradley EC (1988) Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma. J Clin Oncol 6:409–424
Sosman JA, Kohler PC, Hank J, Moor KH, Bechhofer R, Storer B, Sondel PM (1988) Repetitive weekly cycles of recombinant human interleukin-2:Responses of renal carcinoma with acceptable toxicity. JNCI 80:60–63
Fisher RI, Coltman CA, Doroshow JH, Rayner AA, Hawkins MJ, Mier JW, Wiernik P, McMannis JD, Weiss GR, Margolin KA, Gemlo BT, Hoth DF, Parkinson DR, Paietta E (1988) Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 108:518–523
Gambacorti-Passerini C, Radrizzani M, Marolda R, Belli F, Sciorelli G, Galazka AR, Schindler JD, Cascinelli N, Parmiani G (1988) In vivo activation of lymphocytes in melanoma patients receiving escalating doses of recombinant interleukin-2. Int J Cancer 41:700–706.
Oshimi K, Oshimi Y, Akutsu M, Takei Y, Saito H, Okada M, Mizoguchi H (1986) Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells. Blood 68:938–948
Lotzova E, Savary CA, Herberman RB (1987) Induction of NK cell activity against fresh human leukemia in culture with interleukin 2. J Immunol 138:2718–2727
Fierro MT, Liao XS, Lusso P, Bonferroni M, Matera L, Cesano A, Lista P, Arione R, Forni G, Foa R (1988) In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity. Leukemia 2:50–54
Adler A, Chervenick PA, Whiteside TL, Lotzová E, Herberman RB (1988) Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission. Blood 71:709–716
Lotzová E, Savary CA, Herberman RB, Dicke KA (1986) Can NK cells play a role in therapy of leukemia? Nat Immun Cell Growth Regul 5:61–63
Ludwig W-D, Bartram CR, Ritter J, Raghavachar A, Hiddemann W, Heil G, Harbott J, Seibt-Jung H, Teichmann JV, Riehm H (1988) Ambiguous phenotypes and genotypes in 16 children with acute leukemia as characterized by muliparameter analysis. Blood 71:1518–1528
Strander H (1986) Interferon treatment of human neoplasia. Effects on the immune system (IFNs and NK cells). In:Klein G, Weinhaus S (eds) Advances in cancer research, vol 46. Academic, New York, pp 44–54
Brunda MJ, Bellantoni D, Sulich V (1987) In vivo anti-tumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Int J Cancer 40:365–371
Itoh K, Shiiba K, Shimizu Y, Suzuki R, Kumagai (1985) Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL-2) in collaboration with interferon-gamma ( IFN-g ). J Immunol 134:3124–3129.
Owen-Schaub LB, Gutterman JU, Grimm EA (1988) Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes:effects of tumor necrosis factor-alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity. Cancer Res 48:788–792
Scheurich P, Thoma B, Uecer U Pfizenmaier K (1987) Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha:Induction of TNF receptors on human T cells and TNF-alpha mediated enhancement of T cell responses. J Immunol 138:1786–1790
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag, Berlin Heidelberg
About this paper
Cite this paper
Teichmann, J.V., Ludwig, WD., Adler, E., Thiel, E. (1990). Interleukin-2-Induced Lymphokine-Activated Killer (LAK) Cells Against Human Leukemia: Improvement of Cytotoxicity by Combinations of Lymphokines or Cytokines. In: Freund, M., Link, H., Welte, K. (eds) Cytokines in Hemopoiesis, Oncology, and AIDS. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-75510-1_36
Download citation
DOI: https://doi.org/10.1007/978-3-642-75510-1_36
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-52281-2
Online ISBN: 978-3-642-75510-1
eBook Packages: Springer Book Archive